Cefpirom in the treatment for inflammatory respiratory diseases

Abstract

The efficacy of a new cephalosporin of the third generation — Cefpirom (Roussel Uclaf) — was studied in a group of 22 patients with inflammatory respiratory diseases. All patients were divided into three groups: the 1-st group consisted of 14 patients with the severe course of pneumonia, the 2-nd group — of 4 patients with the exacerbation of chronic purulent obstructive bronchitis and the 3-rd group — of 4 patients with cystic fibrosis.
The examination of all patients included physical checkup, laboratory and roentgenologic examination, electrocardiography, study of external respiration and bacteriological examination of sputum. The antibiotic q sensitivity to Cefpirom was studied by the agar diffusion method using standard discs provided by the Roussel Uclaf company.
Cefpirom was prescribed depending on the disease seventy in a dose of 2—4 g divided into 2 slow intravenous infusions every 12 hours. The therapy was ceased after 2—3 days of afebrile temperature, if the differential blood count became normal.
12 of 14 patients with pneumonia had positive dynamics after the treatment with Cefpirom. The recovery was achieved in 64.3% of cases, and the clinical improvement was achieved in 21.4% of cases. There was no effect in 2 cases. The disease remission was achieved for all patients with exacerbation of chronic purulent bronchitis who were treated with Cefpirom. For patients with cystic fibrosis the clinical effect was observed in 3 of 4 cases (75%).
Cefpirom in the given caused few or no side effects and was low toxic.
This study demonstrated that Cefpirom in daily doses of 2—4 g was effective for treating inflammatory respiratory diseases.